{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"A randomized, open-label study evaluating the efficacy and safety of cemacabtagene ansegedleucel in participants with minimal residual disease after response to first line therapy for large B-cell lymphoma ALPHA3)","item":"https:\/\/www.regionalcancercare.org\/trials\/a-randomized-open-label-study-evaluating-the-efficacy-and-safety-of-cemacabtagene-ansegedleucel-in-participants-with-minimal-residual-disease-after-response-to-first-line-therapy-for-large-b-cell-lym\/#breadcrumbitem"}]}